WSWilliam S. Stevenson

William S. Stevenson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William S. Stevenson has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Growth factor independent 1B is a metabolic regulator that exerts pleiotropic effects on platelet function

    by Marie-Christine Morel-Kopp, Marie Levade, Lucinda Beutler, Qiang Chen, Jad Othman, Pascal Steffen, Matthew J. McKay, Mark P. Molloy, Maria V. Selvadurai, Helena P.H. Liang, et al.


  • Open Access

    In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

    by John E. Pimanda, Julie A.I. Thoms, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C. Nunez, Purvi M. Kakadia, Russell Pickford, et al.

    Introduction: Hypomethylating agents (HMAs) are the mainstay of treatment for high-risk myelodysplasia (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-

  • Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma

    by Grace K. Gifford, Andrew J. Gifford, Qian Chen, Yandong Shen, Sara Gabrielli, Anthony J. Gill, William S. Stevenson, Oliver Giles Best

    Fatty acid synthesis is crucial in supporting the survival and proliferation of multiple forms of cancer. The high metabolic demands of fatty acid synthesis are regulated by the AMP-activated kinase and activity of the fatty acid synthase enzyme. In this study, the roles of these enzymes in diffuse large B-cell lymphoma (DLBCL) were investigated by genetic knock-down and pharmacological activation of AMP-activated kinase by metformin, and selective inhibition of fatty acid synthase using the novel drug Fasnall. We observed distinct heterogeneity and adaptive plasticity of lipid metabolism in a panel of DLBCL cell lines and demonstrate the therapeutic potential of inhibiting fatty acid synthesis in a subset of DLBCL cells. The translational relevance of these in vitro data is supported by the strong correlation between AMP-activated protein kinase expression in primary DLBCL samples and disease relapse. Inhibition of fatty acid synthase with Fasnall may represent a therapeutic option for DLBCL that preferentially subverts to de novo fatty acid synthesis.


  • A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons

    by William Stevenson, Jamie Bryant, Rochelle Watson, Rob Sanson-Fisher, Christopher Oldmeadow, Frans Henskens, Christina Brown, Sundra Ramanathan, Campbell Tiley, Anoop Enjeti, et al.

    Purpose: Individuals diagnosed with a high-grade hematological malignancy are at high risk for psychosocial distress. This study aimed to examine the effectiveness of a web-based information tool and nurse delivered telephone support in reducing: (i) unmet information needs; (ii) depression; and (iii) anxiety, among hematological cancer patients and their support persons (SPs). Methods: Patients with a new diagnosis of acute myeloid leukemia, acute lymphoblastic leukemia, Burkitt lymphoma, or lymphoblastic lymphoma and their SPs were enrolled in a prospective multi-site randomized trial. Participants received either access to an online information tool and telephone support from a hematology nurse, or usual care. Outcome data were collected 2, 4, 8, and 12 weeks post-recruitment. The primary endpoint was unmet information needs. Results: Data from 60 patients and 15 SPs were included in the analysis. There were no statistically significant differences in unmet information needs, depression or anxiety between intervention and control groups for patients. Patients in both groups demonstrated a decrease in information needs over the intervention period. Post hoc analyses revealed that patients who did not achieve remission with the first cycle of treatment experienced increased anxiety from 4 weeks until the end of the study (p = 0.008). Conclusions: A web-based information tool and nurse delivered telephone support did not reduce unmet information needs, depression or anxiety among hematological cancer patients, however this finding is inconclusive given the low power of the study. Implications for Psychosocial Providers or Policy: Patients who do not achieve remission are at high risk of anxiety, and may benefit from targeted psychological intervention.